Because..... Amgen's new drugs suck Kyprolis ain't growing enough....stalled US sales for the last 2 years Imlygic ain't selling Corlanor is a dog with fleas Repatha now dreams of $M dollar sales not $B Blincyto - Limited sales cuz no one wants continuous infusion Erenumab - Teva, Lilly and Adler breathing down your throats and you have to share whatever is left with Novartis Amgen's old drugs Enbrel - Each day Humira kills you in both rheum and derm. Orals are coming to RA Neulasta/ Neupogen - Biosimilars are knocking. Onpro can only stave off so much Aranesp/Epogen - Drugs from the 1980's.....you are lucky to still be selling at all Vectibix - Amgen's failure forray into therapeutic oncology Amgen's semi-old drugs Prolia/Xgeva - You never lived up to your $5-6B potential so Jim Daley was fired. But at $1.5B+ after 7 years you are solid and sadly the best driver of growth despite being limited. You are at best a B player, solid but cannot hold the company on your back Sensipar - Same thing but you gonna be generic soon..... The question is: When is Trump letting Amgen bring back $30B in overseas cash Who will Amgen overspend on in desperation Or will Amgen be part of a mega-merger where Bob gets a golden parachute But either route - Expect layoff packages!